Search hospitals > Oregon > Gresham
Legacy Mount Hood Medical Center
Claim this profileGresham, Oregon 97030
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Adenocarcinoma
Conducts research for Prostate Cancer
171 reported clinical trials
6 medical researchers
Summary
Legacy Mount Hood Medical Center is a medical facility located in Gresham, Oregon. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Prostate Cancer and other specialties. Legacy Mount Hood Medical Center is involved with conducting 171 clinical trials across 307 conditions. There are 6 research doctors associated with this hospital, such as Andrew Y. Kee, Colleen C. McCormick, Mei Dong, and Jacqueline Vuky, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
ER positive
2Breast Cancer
Global LeaderER positive
HER2 negative
HER2 positive
Top PIs
Andrew Y. KeeLegacy Good Samaritan Hospital and Medical Center2 years of reported clinical research
Studies Lung Cancer
Studies Prostate Cancer
19 reported clinical trials
60 drugs studied
Colleen C. McCormickLegacy Good Samaritan Hospital and Medical Center4 years of reported clinical research
Studies Ovarian Cancer
Studies Fallopian Tube Cancer
13 reported clinical trials
44 drugs studied
Mei DongLegacy Good Samaritan Hospital and Medical Center1 year of reported clinical research
Studies Breast Cancer
Studies Cancer
15 reported clinical trials
39 drugs studied
Jacqueline Vuky, MDOregon Health and Science University7 years of reported clinical research
Studies Cancer
Studies Non-Small Cell Lung Cancer
10 reported clinical trials
24 drugs studied
Clinical Trials running at Legacy Mount Hood Medical Center
Breast Cancer
Prostate Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Gallbladder Cancer
Cancer
Prostate Adenocarcinoma
Rectal Cancer
Laryngeal Cancer
Recurrence
Radiation and HER2-Targeted Therapy
for Breast Cancer
This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.
Recruiting2 awards Phase 315 criteria
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Legacy Mount Hood Medical Center?
Legacy Mount Hood Medical Center is a medical facility located in Gresham, Oregon. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Prostate Cancer and other specialties. Legacy Mount Hood Medical Center is involved with conducting 171 clinical trials across 307 conditions. There are 6 research doctors associated with this hospital, such as Andrew Y. Kee, Colleen C. McCormick, Mei Dong, and Jacqueline Vuky, MD.